< 生产厂家价格 >

硫酸新霉素

硫酸新霉素用途

Neomycin sulfate是用于预防或治疗细菌感染的氨基糖苷类抗生素。

点击显示

硫酸新霉素名称

[ CAS 号 ]:
1405-10-3

[ 中文名 ]:
硫酸新霉素

[ 英文名 ]:
Neomycin sulfate

[中文别名 ]:

[英文别名 ]:

Neomycin Sulfate
FradioMycin Sulfate
Neomycin Sulphate
Neomycin trisulfate salt hydrate
EINECS 215-773-1
MFCD00037007

硫酸新霉素生物活性

[ 描述 ]:

Neomycin sulfate是用于预防或治疗细菌感染的氨基糖苷类抗生素。

[ 相关类别 ]:

信号通路 >> 抗感染 >> 细菌

信号通路 >> 跨膜转运 >> 钙通道

研究领域 >> 感染

[体外研究]

新霉素通过选择性结合PIP2抑制凝血酶刺激的1,4,5-三磷酸肌醇(IP3)释放,但不抑制32P掺入PI或启动DNA合成[1]。新霉素(10μM-1mM)诱导在用[3H]花生四烯酸预标记的皂苷-透化的人血小板中从磷脂酰肌醇,磷脂酰胆碱和磷脂酰乙醇胺中大量释放[3H]花生四烯酸。此外,新霉素增强凝血酶诱导的花生四烯酸释放。向45Ca2 + -预载的血小板中加入新霉素(100μM)可从细胞内储存中引发45Ca2 +动员[2]。新霉素(0-10mM)以浓度依赖性方式抑制鸟嘌呤5'- [γ-硫代]三磷酸-刺激的洋地黄皂苷-透化的NG108-15细胞中的PLD活性(在100μM下50％抑制)。新霉素同样抑制大鼠脑膜中存在的PLD活性,并在体外用[3H]磷脂酰胆碱作为底物进行测定(65μM时50％抑制)[3]。新霉素(5 mM)引起细胞内Ca2 +水平的可逆性降低,但PMSIns(4,5)P2不是通道活性所必需的[4]。

[参考文献]

[1]. Carney, D.H., et al. Phosphoinositides in mitogenesis: neomycin inhibits thrombin-stimulated phosphoinositide turnover and initiation of cell proliferation. Cell, 1985. 42(2): p. 479-88.

[2]. Nakashima, S., et al. Neomycin is a potent agent for arachidonic acid release in human platelets. Biochem Biophys Res Commun, 1987. 146(2): p. 820-6.

[3]. Liscovitch, M., et al., Inhibition of neural phospholipase D activity by aminoglycoside antibiotics. Biochem J, 1991. 279 ( Pt 1): p. 319-21.

[4]. Huang K, et al. CRAC channel is inhibited by neomycin in a Ptdlns(4,5)P2-independent manner. Cell Biochem Funct. 2015 Mar;33(2):97-100.

[相关活性小分子]

硫酸新霉素物理化学性质

[ 沸点 ]:
1046.1ºC at 760 mmHg

[ 熔点 ]:
>187°C (dec.)

[ 分子式 ]:
C₂₃H₅₂N₆O₂₅S₃

[ 分子量 ]:
908.88

[ 闪点 ]:
586.5ºC

[ PSA ]:
436.09000

[ 外观性状 ]:
黄褐色粉末

[ 蒸汽压 ]:
0mmHg at 25°C

[ 折射率 ]:
56 ° (C=10, H2O)

[ 储存条件 ]:
2-8°C

[ 稳定性 ]:
Stable. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
H2O: 50 mg/mL As a stock solution. Stock solutions should be filter sterilized and stored at 2-8°C. Stable at 37°C for 5 days.

硫酸新霉素MSDS

详细MSDS(安全技术说明书)

硫酸新霉素毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: QP4375000

CHEMICAL NAME :: Neomycin, sulfate (salt)

CAS REGISTRY NUMBER :: 1405-10-3

LAST UPDATED :: 199701

WISWESSER LINE NOTATION :: T6OTJ CZ DQ EQ F1Z BO- CT5OTJ B1Q DQ EO- CL6TJ AZ BQ EZ DO- BT6OTJ CZ DQ EQ F1Z &WSQQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Human

REFERENCE :: 85DKA8 "Cutaneous Toxicity, Proceedings of the 3rd Conference, 1976," Drill, V.A., and P. Lazar, eds., New York, Academic Press, Inc. 1977 Volume(issue)/page/year: -,127,1977 ** ACUTE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 12600 mg/kg/7D

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - hallucinations, distorted perceptions Behavioral - anorexia (human)

REFERENCE :: ARSUAX Archives of Surgery (Chicago). (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-61, 1920-50; V.81- 1960- Volume(issue)/page/year: 111,822,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 12,597,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >8 gm(base)/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AACHAX Antimicrobial Agents and Chemotherapy (1961-70). (Ann Arbor, MI) 1961-70. For publisher information, see AMACCQ. Volume(issue)/page/year: -,138,1963

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 305 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANTCAO Antibiotics and Chemotherapy (Washington, DC). (Washington, DC) V.1-12, 1951-62. For publisher information, see CLMEA3. Volume(issue)/page/year: 8,198,1958

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 190 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 18,444,1973

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 17400 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AITEAT Archivum Immunologiae et Therapiae Experimentalis. (Ars Polona, POB 1001, 00-068 Warsaw 1, Poland) V.10- 1962- Volume(issue)/page/year: 10,947,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 142 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 119,493,1967

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intracerebral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 32 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 7,361,1965

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: >250 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Ear) - change in acuity

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 33,320,1975 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 280 mg/kg/7D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in bladder weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases

REFERENCE :: CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 109,77,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 560 mg/kg/7D-I

TOXIC EFFECTS :: Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes

REFERENCE :: CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 109,77,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 2 gm/kg/8D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Ear) - change in acuity Sense Organs and Special Senses (Ear) - changes in cochlear structure or function Related to Chronic Data - death

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 33,320,1975 *** REVIEWS *** TOXICOLOGY REVIEW PMMDAE Panminerva Medica. (Edizioni Minerva Medica, Casella Postale 491, Turin, Italy) V.1- 1959- Volume(issue)/page/year: 16,9,1974 *** U.S. STANDARDS AND REGULATIONS *** EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION FEREAC Federal Register. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year: 54,7740,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3700 No. of Facilities: 3566 (estimated) No. of Industries: 23 No. of Occupations: 33 No. of Employees: 180078 (estimated) No. of Female Employees: 143663 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9498 No. of Facilities: 1014 (estimated) No. of Industries: 5 No. of Occupations: 11 No. of Employees: 16279 (estimated) No. of Female Employees: 12693 (estimated)

点击显示

硫酸新霉素安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H317-H334

[ 警示性声明 ]:
P261-P280-P342 + P311

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
R42/43

[ 安全声明 (欧洲) ]:
23-36/37-45-22-36-24/25

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
QP4375000

[ 海关编码 ]:
2941909000

硫酸新霉素海关

[ 海关编码 ]: 2941909000

硫酸新霉素文献

Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.

Lancet Infect. Dis. 13(4) , 328-41, (2013)

Many meta-analyses have shown reductions in infection rates and mortality associated with the use of selective digestive decontamination (SDD) or selective oropharyngeal decontamination (SOD) in inten...

Clearance of nasal Staphylococcus aureus colonization with triple antibiotic ointment.

Journal. of. Drugs in. Dermatology. 11(12) , 1490-2, (2012)

The prevalence of Staphylococcus aureus colonization of healthcare workers is reported at 30%, with colonization rates for methicillin-resistant S aureus (MRSA) reported between 2.0% and 8.5% among in...

Acute otitis externa: an update.

Am. Fam. Physician 86(11) , 1055-61, (2012)

Acute otitis externa is a common condition involving inflammation of the ear canal. The acute form is caused primarily by bacterial infection, with Pseudomonas aeruginosa and Staphylococcus aureus the...

更多文献